A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

NCT07234162 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

218

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral T-cell Lymphoma

Interventions

DRUG: Golidocitinib
DRUG: Chidamide
DRUG: Pralatrexate
DRUG: Gemcitabine
DRUG: Belinostat

Sponsor

Dizal Pharmaceuticals